Castle Creek Biosciences, Inc.

Exton, PA · Founded 2018 · Biotech · Private

Therapeutics for rare genetic and orphan diseases

Claim this profile

Follows are private to you and power your alerts

Updated · castlecreekbio.com

Sector
Biotech
Headquarters
Exton, PA
Founded
2018
Latest Form D
$75M, Feb 2025
Total capital
$840M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$840M
6 Form D · last Feb 2025
20 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20182019202020212022202320242025FEDERAL ↑EQUITY ↓Cumulative $840M1st Form D$561M2nd Form D$54.6M5th Form D$113M6th Form D$75M
2018202020222024FEDERAL ↑EQUITY ↓Cumulative $840M5th Form D$113M

Latest events

  • Private capital raisedForm D · SEC · 6th filing$75M
  • Private capital raisedForm D · SEC · 5th filing$113M
  • Private capital raisedForm D · SEC · 4th filing$11.8M
  • Private capital raisedForm D · SEC · 3rd filing$25M
  • Private capital raisedForm D · SEC · 2nd filing$54.6M
  • Private capital raisedForm D · SEC · 1st filing$561M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Antonio GraciasDirectorNamed in SEC Form D filings
  • Babar J. GhiasExecutive OfficerNamed in SEC Form D filings
  • Darien ParhadExecutive OfficerNamed in SEC Form D filings
  • David BrillDirectorNamed in SEC Form D filings
  • Gregory J. MacMichaelExecutive OfficerNamed in SEC Form D filings
  • Gregory Bradford WujekExecutive OfficerNamed in SEC Form D filings
Show all 14 people
  • Jeffrey AroninDirectorNamed in SEC Form D filings
  • Jude SullivanExecutive OfficerNamed in SEC Form D filings
  • Mark J. GrafDirectorNamed in SEC Form D filings
  • Mary Bradford SpellmanExecutive OfficerNamed in SEC Form D filings
  • Matthew CrabtreeDirectorNamed in SEC Form D filings
  • Matthew J. GantzExecutive Officer, DirectorNamed in SEC Form D filings
  • Patrick J. MorrisDirectorNamed in SEC Form D filings
  • W. Bradford MiddlekauffExecutive OfficerNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .